Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

An Alternative Safety Profiling Algorithm (ASPA) to transform next generation risk assessment into a structured and transparent process

  • Leist, Marcel
  • Pastor Maeso, Manuel
  • Luijten, Mirjam
Next generation risk assessment (NGRA) strategies use animal-free new approach methodologies (NAMs) to generate information concerning chemical hazard, toxicokinetics (ADME), and exposure. The information from these major pillars of data gathering is used to inform risk assessment and classification decisions. While the required types of data are widely agreed upon, the processes for data collection, integration and reporting, as well as several decisions on the depth and granularity of required data, are poorly standardized. Here, we present the Alternative Safety Profiling Algorithm (ASPA), a broad-purpose, transparent, and reproducible risk assessment workflow that allows documentation and integration of all types of information required for NGRA. ASPA aims to make safety assessments fully traceable for the recipient (e.g., a regulator), delineating which steps and decisions have led to the final outcome and why certain decisions were made. An overarching objective of ASPA is to ensure that identical data input yields identical outcomes in the hands of independent assessors. Therefore, ASPA is not just a data gathering workflow; it also considers data interdependencies and requires precise justification of intermediate decisions. This includes the monitoring and assessment of uncertainties. To assist users, the ASPA-assist software was developed. It formalizes the reporting process in a reproducible and standardized fashion. By guiding an operator step-by-step through the ASPA workflow, a complete and comprehensive report is assembled, whereby all data, methods, operator activities, and intermediate decisions are recorded. Practical examples illustrating the broader applicability of ASPA across various regulations and problem formulations are provided through case studies., This work has received funding from the European Union's Horizon 2020 research and innovation program under grant No. 964537 (RISK-HUNT3R), 963845 (ONTOX), and 965406 (PrecisionTox), which are all part of the ASPIS project cluster. Some authors have also been supported by PARC (The European Partnership for the Assessment of Risks from Chemicals). This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057014.
Repisalud
Publicación Artículo científico (JournalArticle)

New approach methods to assess developmental and adult neurotoxicity for regulatory use: a PARC work package 5 project

  • Tal, Tamara
  • Myhre, Oddvar
  • Fritsche, Ellen
  • Rüegg, Joëlle
  • Craenen, Kai
  • Aiello-Holden, Kiara
  • Agrillo, Caroline
  • Babin, Patrick J
  • Escher, Beate I
  • Dirven, Hubert
  • Hellsten, Kati
  • Dolva, Kristine
  • Hessel, Ellen
  • Heusinkveld, Harm J
  • Hadzhiev, Yavor
  • Hurem, Selma
  • Jagiello, Karolina
  • Judzinska, Beata
  • Klüver, Nils
  • Knoll-Gellida, Anja
  • Kühne, Britta A
  • Leist, Marcel
  • Lislien, Malene
  • Lyche, Jan L
  • Müller, Ferenc
  • Colbourne, John K
  • Neuhaus, Winfried
  • Pallocca, Giorgia
  • Seeger, Bettina
  • Scharkin, Ilka
  • Scholz, Stefan
  • Spjuth, Ola
  • Torres-Ruiz, Mónica
  • Bartmann, Kristina
In the European regulatory context, rodent in vivo studies are the predominant source of neurotoxicity information. Although they form a cornerstone of neurotoxicological assessments, they are costly and the topic of ethical debate. While the public expects chemicals and products to be safe for the developing and mature nervous systems, considerable numbers of chemicals in commerce have not, or only to a limited extent, been assessed for their potential to cause neurotoxicity. As such, there is a societal push toward the replacement of animal models with in vitro or alternative methods. New approach methods (NAMs) can contribute to the regulatory knowledge base, increase chemical safety, and modernize chemical hazard and risk assessment. Provided they reach an acceptable level of regulatory relevance and reliability, NAMs may be considered as replacements for specific in vivo studies. The European Partnership for the Assessment of Risks from Chemicals (PARC) addresses challenges to the development and implementation of NAMs in chemical risk assessment. In collaboration with regulatory agencies, Project 5.2.1e (Neurotoxicity) aims to develop and evaluate NAMs for developmental neurotoxicity (DNT) and adult neurotoxicity (ANT) and to understand the applicability domain of specific NAMs for the detection of endocrine disruption and epigenetic perturbation. To speed up assay time and reduce costs, we identify early indicators of later-onset effects. Ultimately, we will assemble second-generation developmental neurotoxicity and first-generation adult neurotoxicity test batteries, both of which aim to provide regulatory hazard and risk assessors and industry stakeholders with robust, speedy, lower-cost, and informative next-generation hazard and risk assessment tools.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

DockTox: Targeting molecular initiating events in organ toxicity through molecular docking

  • Ortega-Vallbona, Rita Carmen
  • Talavera-Cortés, David
  • Carpio, Laureano E.
  • Coto Palacio, Jessica
  • Roncaglioni, Alessandra
  • García de Lomana, Marina
  • Gadaleta, Domenico
  • Benfenati, Emilio
  • Gozalbes, Rafael
  • Serrano-Candelas, Eva
[EN] Adverse Outcome Pathways (AOPs) in toxicology describe the sequence of key events from chemical exposure to adverse outcomes, facilitating the development of predictive models. The EU ONTOX project uses this framework to predict liver, developmental brain, and kidney toxicity without animal testing. Focusing on Molecular Initiating Events (MIEs), more concretely on the interaction of chemicals with key proteins, we have developed an automated workflow for docking small molecules onto over 20 pre-processed protein structures, implemented in the online tool DockTox. This tool generates conformers of small molecules, performs docking on MIE-associated proteins, and provides binding energy, interacting residues, and interaction maps. Additionally, it compares the interactions to a reference list of known ligands, producing an interaction fraction as an additional similarity measure. Evaluation of the docking workflow¿s predictive performance on Peroxisome Proliferator-Activated Receptor ¿ (PPAR¿) showed that interaction fraction values are more informative than binding energy alone for distinguishing binders from non-binders. This unique feature enhances the understanding of target protein interactions. DockTox supports the virtual screening of small molecules targeting MIE-associated proteins, offering insights into binding energies and interaction profiles. It is a valuable tool for anticipating adverse outcomes from chemical exposure in a tiered risk assessment approach, This work was performed in the context of the ONTOX project (https://ontox-project.eu/) , which has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No 963845. ONTOX is part of the ASPIS project cluster (https://aspis-cluster.eu/) . We gratefully acknowledge the financial support of the Agencia Valenciana de la Investigacion (AVI, https://innoavi. es/en/) by its program Innodocto (Reference number INNTA3/2022/13) . This action has been financed by the European Union through the European Regional Development Fund (ERDF) of the Valencian Community 2021-2027.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Report of the First ONTOX Stakeholder Network Meeting: Digging Under the Surface of ONTOX Together With the Stakeholders

  • Diemar, Michael G.
  • Vinken, Mathieu
  • Teunis, Marc
  • Krul, Cyrille A. M.
  • Busquet, Francois
  • Zajac, Julia Dominika
  • Kandarova, Helena
  • Corvi, Raffaella
  • Rosso, Matteo Z.
  • Kharina, Anastasiia
  • Bryndum, Louise Stab
  • Santillo, Michael
  • Bloch, Denise
  • Kucheryavenko, Olena
  • Panagiotakos, Demosthenes
  • Rogiers, Vera
  • Beekhuijzen, Manon
  • Giusti, Arianna
  • Najjar, Abdulkarim
  • Courage, Carol
  • Koenig, Torben
  • Kolle, Susanne
  • Boonen, Harrie
  • Dhalluin, Stephane
  • Boberg, Julie
  • Müller, Boris P.
  • Kukic, Predrag
  • Ritskes-Hoitinga, Merel
  • Grasselli, Elena
  • Zietek, Tamara
  • Stoddart, Gilly
  • Heusinkveld, Harm J.
  • Castell, José V.
  • Benfenati, Emilio
  • Yang, Huan
  • Perera-Del-Rosario, Simón
  • Paini, Alicia
  • Kramer, Nynke I.
  • Hartung, Thomas
  • Janssen, Manoe
  • Fritsche, Ellen
  • Jennen, Danyel G. J.
  • Piumatti, Matteo
  • Rathman, James
  • Marusczyk, Jörg
  • Milec, Lucia
  • Roggen, Erwin L.
© The Author(s) 2024., The first Stakeholder Network Meeting of the EU Horizon 2020-funded ONTOX project was held on 13–14 March 2023, in Brussels, Belgium. The discussion centred around identifying specific challenges, barriers and drivers in relation to the implementation of non-animal new approach methodologies (NAMs) and probabilistic risk assessment (PRA), in order to help address the issues and rank them according to their associated level of difficulty. ONTOX aims to advance the assessment of chemical risk to humans, without the use of animal testing, by developing non-animal NAMs and PRA in line with 21st century toxicity testing principles. Stakeholder groups (regulatory authorities, companies, academia, non-governmental organisations) were identified and invited to participate in a meeting and a survey, by which their current position in relation to the implementation of NAMs and PRA was ascertained, as well as specific challenges and drivers highlighted. The survey analysis revealed areas of agreement and disagreement among stakeholders on topics such as capacity building, sustainability, regulatory acceptance, validation of adverse outcome pathways, acceptance of artificial intelligence (AI) in risk assessment, and guaranteeing consumer safety. The stakeholder network meeting resulted in the identification of barriers, drivers and specific challenges that need to be addressed. Breakout groups discussed topics such as hazard versus risk assessment, future reliance on AI and machine learning, regulatory requirements for industry and sustainability of the ONTOX Hub platform. The outputs from these discussions provided insights for overcoming barriers and leveraging drivers for implementing NAMs and PRA. It was concluded that there is a continued need for stakeholder engagement, including the organisation of a ‘hackathon’ to tackle challenges, to ensure the successful implementation of NAMs and PRA in chemical risk assessment., The ONTOX project received funding from the European Union’s Horizon 2020 Research and Innovation programme, under Grant Agreement No. 963845., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immune digital twins for complex human pathologies: applications, limitations, and challenges

  • Niarakis, Anna
  • Montagud, Arnau
  • Valencia, Alfonso
Niarakis, Anna et al., Digital twins represent a key technology for precision health. Medical digital twins consist of computational models that represent the health state of individual patients over time, enabling optimal therapeutics and forecasting patient prognosis. Many health conditions involve the immune system, so it is crucial to include its key features when designing medical digital twins. The immune response is complex and varies across diseases and patients, and its modelling requires the collective expertise of the clinical, immunology, and computational modelling communities. This review outlines the initial progress on immune digital twins and the various initiatives to facilitate communication between interdisciplinary communities. We also outline the crucial aspects of an immune digital twin design and the prerequisites for its implementation in the clinic. We propose some initial use cases that could serve as "proof of concept" regarding the utility of immune digital technology, focusing on diseases with a very different immune response across spatial and temporal scales (minutes, days, months, years). Lastly, we discuss the use of digital twins in drug discovery and point out emerging challenges that the scientific community needs to collectively overcome to make immune digital twins a reality., This work is based on work during the three-week workshop on Building Immune Digital Twins, which was made possible by the support of the Institut Pascal, University of Paris-Saclay, France, via the program Investissements d’avenir, ANR-11-IDEX-0003-0. We would also like to thank Genopole for supporting the workshop. The authors also acknowledge the following support: AN was supported by a public-private partnership grant (CIFRE contract, no. 2020/0766) with SANOFI-AVENTIS R&D. R.L. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038), and the National Institutes of Health (grants R01 GM127909, R01 AI135128, and R01 HL169974). L.C.M., B.S., and L.G. acknowledge support from the European Commission (grants H2020-SC1-BHC-11-2020 963845 and Digital Europe EDITH-CSA 101083771). M.L.B. acknowledges support from the National Institutes of Health (grants R24 GM137787 and P41 EB023912). L.L.F. acknowledges financial support from the Defense Advanced Research Projects Agency (grant HR00112220038). L.H. acknowledged support from NIH/NCI Transition Career Development Award to Promote Diversity (K22-CA237857). L.S.V. acknowledges support from the National Institutes of Health (grants R01 AI135128, R01 HL169974, K25 AI175668). P.H. acknowledges support from the Prime Ministers’ Research Fellowship (PMRF). H.B. acknowledges the support of ZonMw (Grant No. 10430012010015) N.N. acknowledges support from the Knowledge Foundation (20200017) and The Swedish Fund for Research Without Animal Experiments. A.M., J.C.C., and A.V. acknowledge support from the European Commission (grants CREXDATA 101092749, PerMedCoE 951773, and EDITH-CSA 101083771). F.M. acknowledges support from the Italian Ministry of Health (grant “Ricerca Corrente” Linea 4 Project 5 and “5 per 1000–2021” Grant No. 5M-2021-23683787) and the European Commission with HORIZON programme (Grant No. 101046203—BY-COVID). J.A.G. acknowledges support from the National Institutes of Health (grants U24 EB028887) and the National Science Foundation (grants NSF 2303695, NSF 2120200, and NSF 1720625). G.A. and C.C. acknowledge support from the National Institutes of Health Award UO1EB025825 and the Defense Advanced Research Projects Agency through Cooperative Agreement D20AC00002 awarded by the U.S. Department of the Interior (DOI), Interior Business Center. K.R. was supported by the BMBF (Federal Ministry of Education and Research) in DAAD project 57616814 (SECAI, School of Embedded and Composite AI) as part of the program Konrad Zuse Schools of Excellence in Artificial Intelligence. Further, KR was supported by the imSAVAR and the CERTAINTY project. imSAVAR received funding from the Innovative Medicine Initiative 2 Joint Undertaking (JU) under grant agreement No 853988. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and JDRF INTERNATIONAL. The CERTAINTY project is funded by the European Union (Grant Agreement 101136379)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An Alternative Safety Profiling Algorithm (ASPA) to transform next generation risk assessment into a structured and transparent process

  • Leist, Marcel
  • Pastor Maeso, Manuel
  • Luijten, Mirjam
Next generation risk assessment (NGRA) strategies use animal-free new approach methodologies (NAMs) to generate information concerning chemical hazard, toxicokinetics (ADME), and exposure. The information from these major pillars of data gathering is used to inform risk assessment and classification decisions. While the required types of data are widely agreed upon, the processes for data collection, integration and reporting, as well as several decisions on the depth and granularity of required data, are poorly standardized. Here, we present the Alternative Safety Profiling Algorithm (ASPA), a broad-purpose, transparent, and reproducible risk assessment workflow that allows documentation and integration of all types of information required for NGRA. ASPA aims to make safety assessments fully traceable for the recipient (e.g., a regulator), delineating which steps and decisions have led to the final outcome and why certain decisions were made. An overarching objective of ASPA is to ensure that identical data input yields identical outcomes in the hands of independent assessors. Therefore, ASPA is not just a data gathering workflow; it also considers data interdependencies and requires precise justification of intermediate decisions. This includes the monitoring and assessment of uncertainties. To assist users, the ASPA-assist software was developed. It formalizes the reporting process in a reproducible and standardized fashion. By guiding an operator step-by-step through the ASPA workflow, a complete and comprehensive report is assembled, whereby all data, methods, operator activities, and intermediate decisions are recorded. Practical examples illustrating the broader applicability of ASPA across various regulations and problem formulations are provided through case studies., This work has received funding from the European Union's Horizon 2020 research and innovation program under grant No. 964537 (RISK-HUNT3R), 963845 (ONTOX), and 965406 (PrecisionTox), which are all part of the ASPIS project cluster. Some authors have also been supported by PARC (The European Partnership for the Assessment of Risks from Chemicals). This project has received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057014.